Workflow
Managed Care
icon
Search documents
Wall Street Sees an 18% Upside to Elevance Health (ELV)
Yahoo Finance· 2025-12-17 13:11
Core Viewpoint - Elevance Health, Inc. (NYSE:ELV) is considered a strong investment opportunity, with analysts projecting significant upside potential based on recent evaluations and financial performance [1][2][3]. Group 1: Analyst Recommendations - Seth Klarman holds a $426 million stake in Elevance Health as of Q3 2025, with an average price target suggesting a 10% upside and a Street high indicating an 18% upside [1]. - TD Cowen analyst Ryan Langston reiterated a Buy recommendation and raised the target price from $380 to $400, naming Elevance Health as its "Best Idea for 2026" despite challenges in the managed care sector [2]. - TD Cowen's EPS estimate for Elevance Health was lifted to $27.25, indicating a 12.7x multiple of the 2027 EPS projection [3]. Group 2: Financial Performance - Elevance Health reported Q3 2025 operating revenue of $50.1 billion, reflecting a 12% year-over-year increase [5]. - The diluted EPS for Q3 stood at $5.32, with adjusted diluted EPS at $6.03, driven by robust growth in premiums and higher net investment income [5]. - The growth was partially offset by a decline in overall medical enrollment due to Medicaid re-verification and rising cost pressures [5]. Group 3: Risk/Reward Profile - Elevance Health is noted to have a more balanced risk/reward profile compared to other managed care companies, attributed to its stable group health plan and careful estimates regarding Medicare Advantage and Medicaid [4].
Should You Hold Centene (CNC)?
Yahoo Finance· 2025-12-10 13:30
Core Insights - Hotchkis & Wiley Mid-Cap Value Fund reported strong performance in Q3 2025, outperforming the Russell Midcap Value Index with a gain of 7.74% compared to 6.18% for the index, driven by enthusiasm over AI, a Federal Reserve rate cut, and robust corporate earnings [1] Company Overview - Centene Corporation (NYSE:CNC) is a healthcare enterprise focused on managed Medicaid, serving approximately 28 million at-risk health insurance enrollees [3] - As of December 09, 2025, Centene's stock closed at $38.08 per share, with a market capitalization of $18.717 billion [2] Performance Metrics - Centene's one-month return was 5.19%, but it experienced a significant decline of 33.08% over the past 52 weeks [2] - Following a disappointing quarterly earnings report, Centene's shares fell during the quarter, trading at approximately 4.8 times normal earnings, indicating potential attractiveness as a market leader in a growing Medicaid market [3] Market Outlook - The Medicaid market is projected to grow at a rate of 6% per year from 2020 to 2027, driven by increased spending per member, suggesting a favorable growth environment for Centene [3] - Despite the potential of Centene as an investment, there is a belief that certain AI stocks may offer greater upside potential with less downside risk [4]
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026
The Motley Fool· 2025-12-09 20:05
Core Viewpoint - UnitedHealth Group is expected to rebound in stock performance by 2026, despite facing challenges in 2023 due to misjudgments in cost projections and a significant drop in stock price [3][11][19] Company Overview - UnitedHealth Group is a Minnesota-based managed care company, the largest in the U.S. with approximately 23% market share, offering Medicare and Medicaid supplemental plans and health insurance for individuals and businesses [6][15] - The company has consistently raised its dividend for the last 16 years, currently yielding 2.25% per share, which is above the healthcare sector average of 1.6% [16][15] Financial Performance - In 2023, UnitedHealth Group's stock price has decreased by about 35%, primarily following a disappointing first-quarter earnings report that missed analysts' expectations for the first time since 2008 [7][11] - The third-quarter earnings report showed revenue of $113.2 billion, a 12% increase from the previous year, but earnings fell sharply to $4.3 billion from $8.7 billion in Q3 2024, with profit margins dropping to 2.1% from 6% [13][14] Challenges and Solutions - The company miscalculated service costs when setting 2025 customer premiums, leading to an increase in medical costs by $6.5 billion, which has impacted profit margins [11][12] - Management plans to rectify these issues by adjusting Medicare Advantage bids and potentially exiting unprofitable markets, targeting a profit margin range of 2% to 4% for 2026 and 2027 [12][11] Market Position and Valuation - UnitedHealth Group's current price-to-earnings ratio is 17.2, significantly lower than its five-year average of 25.2, indicating that the stock is undervalued at present [18][19] - The stock is expected to appreciate as the company addresses its profit margin issues, making it an attractive investment opportunity [19][18]
CVS Health: Investor Day Targets Set Attractive Baseline For 2026 (CVS)
Seeking Alpha· 2025-12-09 19:49
CVS Health Corporation ( CVS ) has been a notable outlier in a managed care industry that's been dealing with significant operational and regulatory pressure, with the stock up over 70% YTD, while most peers are in the red.I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I man ...
CVS Health: Investor Day Targets Set Attractive Baseline For 2026
Seeking Alpha· 2025-12-09 19:49
Group 1 - CVS Health Corporation has shown significant resilience in the managed care industry, with its stock price increasing over 70% year-to-date, contrasting with most peers that are experiencing declines [1] - The managed care industry is currently facing substantial operational and regulatory pressures, impacting the performance of many companies within the sector [1] Group 2 - The investment strategy focuses on identifying companies with strong qualitative attributes, purchasing them at favorable prices based on fundamentals, and maintaining long-term holdings [2] - The portfolio management approach emphasizes avoiding underperforming stocks while maximizing exposure to high-potential investments, often resulting in a 'Hold' rating for companies that do not meet growth or risk thresholds [2]
Alignment Healthcare (NasdaqGS:ALHC) FY Conference Transcript
2025-12-03 16:02
Summary of Alignment Healthcare FY Conference Call (December 03, 2025) Company Overview - **Company**: Alignment Healthcare (NasdaqGS:ALHC) - **Industry**: Medicare Advantage Organization - **Membership**: Over 230,000 members across five states - **Growth Rate**: 46% growth in membership in 2025 - **Margin Improvement**: Expanded margins by 250 basis points in 2025 [3][3] Key Points and Arguments Membership Growth and Retention - **2026 Membership Growth Expectation**: Anticipated growth rate between 20% to 30%, with better-than-expected retention rates potentially pushing it above 30% [6][12] - **Churn Rate**: Historically around 6% to 7% during Annual Enrollment Period (AEP), with the company performing better than the industry average of approximately 16% [11][12] - **Product Design**: Adjustments made based on competitive analysis in various markets, leading to opportunities for growth [10][10] Market Position and Strategy - **California Market**: Represents 84% of membership; the company has room to grow despite approaching 30% to 40% market share in some counties [16][17] - **Expansion Outside California**: Significant growth expected, with a doubling of membership anticipated in states like Nevada, Texas, Arizona, and North Carolina [17][19] Industry Dynamics - **Overall MA Market Outlook**: Expected to be relatively flat due to product exits and competitive dynamics; larger competitors may struggle with medical management infrastructure [21][22] - **Care Delivery Focus**: Emphasis on care delivery capabilities as a core competency, differentiating from competitors who may not manage risk effectively [24][25] Care Delivery Model Enhancements - **Quality Care Initiatives**: Investments in provider relationships and care delivery systems to improve member experience and reduce admissions [30][34] - **Transition of Care Program**: Aimed at ensuring smooth transitions for members post-discharge, with a goal to reduce readmission rates [35][36] Financial Performance and Projections - **Revenue Growth**: Revenue projected to reach $4 billion, with a history of doubling every two years since IPO [29][29] - **MLR (Medical Loss Ratio) Improvement**: Strategies in place to improve new member MLR from approximately 90% at enrollment to low 80s over time [29][29] Regulatory Environment - **Impact of Proposed Rule Changes**: Concerns regarding the elimination of the Health Equity Index reward factor and its potential impact on star ratings for 2027 [41][43] - **Star Ratings**: The company aims to maintain a strong performance in star ratings despite regulatory changes [43][45] Additional Important Insights - **Fee Delegation**: The company has taken over certain functions from Independent Physician Associations (IPAs) to improve care delivery and reduce admissions [37][39] - **Operational Discipline**: Emphasis on maintaining operational discipline in growth strategies to avoid overextending resources [27][28] This summary encapsulates the key insights from the conference call, highlighting the company's growth strategies, market dynamics, and operational focus within the Medicare Advantage sector.
Here’s Why Centene Corporation (CNC) Reduced Its Earnings Outlook
Yahoo Finance· 2025-12-03 12:51
Core Insights - The Carillon Scout Mid Cap Fund's third-quarter 2025 investor letter highlights strong corporate earnings and AI infrastructure momentum as key drivers for the Russell Midcap Index's positive returns [1] - Centene Corporation (NYSE:CNC) is a significant focus, with a one-month return of 5.35% but a substantial 35.07% decline over the past 52 weeks [2][3] Company Overview - Centene Corporation provides managed care services for government-sponsored health plans, targeting under-insured and uninsured families [2][3] - The company recently lowered its earnings guidance due to higher-than-expected utilization in its health plans and ongoing challenges in its Medicaid business [3] Market Performance - Centene's stock closed at $38.81 per share on December 2, 2025, with a market capitalization of $19.08 billion [2] - The stock has faced investor caution, resulting in an 11.1% decline, and it is not among the top 30 most popular stocks among hedge funds [4] Investment Sentiment - While Centene shows potential as an investment, there is a belief that certain AI stocks may offer better upside potential with less downside risk [4]
Evolent Health (NYSE:EVH) FY Conference Transcript
2025-12-02 17:02
Evolent Health Conference Call Summary Company Overview - **Company**: Evolent Health - **Industry**: Managed Care and Healthcare IT - **Focus Areas**: Specialty care management, particularly in oncology, cardiology, and musculoskeletal conditions [3][4] Key Financial Insights - **Revenue Composition**: Two-thirds of Evolent's revenue is linked to the ACA Marketplace and Medicaid, while about one-third is from Medicare Advantage [6] - **2025 Guidance**: Evolent reiterated its 4Q and 2025 guidance, with adjusted EBITDA expected to be $149 million, including $10 million from an asset being divested [32][33] - **Performance Suite**: Expected to generate about 80% of adjusted EBITDA from tech and services, and 20% from risk-based Performance Suites [19][33] Cost Trends and Utilization - **Cost Trends**: Oncology cost trend is under 11%, while cardiology trends are higher due to benefits rush ahead of premium increases [4] - **Impact on Specialty Cost**: Evolent uses risk pool adjustments to isolate its impact on specialty cost trends, with a growing pipeline of Medicare Advantage business [6][10] Value Creation and Cost Savings - **Evidence-Based Pathways**: Evolent aims to increase adherence to evidence-based care from 65% to about 85%, which reduces costs by ensuring the right treatment is provided initially [9][10] - **Cost Categories**: In oncology, 80% of costs are in therapeutics, with significant savings opportunities in matching therapies to patients. In cardiology, savings come from preventing surgical interventions [12][14] Contractual Protections and Market Dynamics - **Contractual Protections**: Evolent has secured protections around case mix and drug pricing in 90% of contracts, allowing for better risk management [22][24] - **Market Environment**: Health plans are more willing to negotiate favorable terms due to financial pressures, allowing Evolent to secure better contracts [23][25] Future Expectations - **2026 Revenue Outlook**: Evolent expects $750 million in new Performance Suite annual contract value (ACV) with $550 million anticipated to hit in 2026 [29][31] - **EBITDA Expectations**: Minimal EBITDA contribution expected from new contracts in 2026, with a target of reaching a 10% margin by mid to late 2028 [31] Membership and Market Challenges - **Membership Trends**: Declines in Medicaid membership and Medicare Advantage membership are impacting revenue, with expectations of a 40-60% shrinkage in ACA Marketplace revenue [36][42] - **Operational Investments**: Evolent invested $10 million in AI and efficiency improvements to enhance clinical operations and reduce costs [37] Strategic Decisions - **Divestiture of ECP**: Evolent decided to divest its ECP business to focus on its core specialty business, which is expected to grow significantly [49][50] - **Use of Proceeds**: Proceeds from the divestiture will be used to pay down high-interest debt, improving cash flow conversion and targeting a leverage ratio of about 5.5 times by year-end [51][52] Conclusion Evolent Health is strategically positioned in the managed care sector, focusing on specialty care management with a strong emphasis on cost reduction through evidence-based practices. The company is navigating market challenges while securing favorable contractual terms and investing in operational efficiencies to drive future growth.
UNH Battles MCR, Optum Bandages: But the Real Wild Card is Washington
ZACKS· 2025-11-28 14:51
Core Insights - UnitedHealth Group Incorporated (UNH) is experiencing increased pressure on profitability due to a rising medical care ratio (MCR), which reached 89.9% in Q3 2025, up from 85.2% a year prior, driven by persistent medical inflation and unpredictable utilization trends [1][8] - The Optum division is a significant growth driver, with revenues increasing by 8.2% year over year to $69.2 billion, representing over 61% of total company sales [1][8] - Regulatory scrutiny surrounding Optum Rx, the pharmacy benefit management arm, has raised concerns among investors, as any potential regulatory actions could impact the broader business [2][8] Company Performance - The MCR increase is pressuring profitability, with Optum Rx contributing 57.4% of Optum's revenues [2][8] - The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is projected at $16.29 per share, indicating a 41.1% decline from the previous year [11] - UnitedHealth's stock has declined by 34.8% year-to-date, compared to a 29% decline in the industry [7][8] Industry Context - Peers such as Centene Corporation and Elevance Health are also facing challenges from rising medical costs, leading to downward revisions in their 2025 outlooks [5][6] - Centene's health benefits ratio increased to 92.7%, reflecting a 27% rise in medical expenses, while Elevance's benefit expense ratio rose to 91.3% [6] - The expiration of enhanced Affordable Care Act subsidies at year-end could lead to higher premiums for millions, prompting potential shifts in enrollment patterns across insurance products [3][4]
Coordinated Care Investments Bring Hope This Holiday Season: Tackling Food Insecurity and Nutrition Gaps in Washington
Prnewswire· 2025-11-25 20:47
Core Insights - Coordinated Care has provided over 18 million meals in Washington since 2020, addressing food insecurity as part of its commitment to increase access to healthy food [1][5] - The organization’s One Million Meals campaign has consistently exceeded annual goals, demonstrating effective community partnerships [2][5] - Coordinated Care Harvest Bucks program offers Medicaid members up to $100 annually for produce prescriptions, enhancing grocery budgets and promoting nutritional health [4][5] Company Initiatives - The One Million Meals campaign began during the COVID-19 pandemic and has shown significant success through collaboration with local partners [2][3] - Coordinated Care's volunteer efforts have included packing meals and supporting local food programs, reflecting a strong community engagement [7] - The organization aims to address whole-person health care needs by integrating food access with healthcare services [5][8] Community Impact - Food insecurity affects approximately 47.4 million people in the U.S., including 13.8 million children, highlighting the importance of Coordinated Care's initiatives [1] - The organization collaborates with various local food banks and health organizations to maximize its impact on community health [2][7] - Coordinated Care's efforts are part of a broader mission to transform community health by addressing nutrition and food access challenges [5][8]